Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: The price we have to pay?

Inflammatory Bowel Diseases

Volumn 14, Issue 7, 2008, Pages 1019-1021

  Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB;

ADULT; ANASTOMOSIS LEAKAGE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; ILEOANAL ANASTOMOSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NOTE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTOCOLECTOMY; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COLONIC POUCHES; HUMANS; INFECTION; POSTOPERATIVE COMPLICATIONS; PROCTOCOLECTOMY, RESTORATIVE;

EID: 47949083532     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20407     Document Type: Note

References (20)

1. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956-962; discussion 962-963.
2. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. Erratum in: N Engl J Med. 2006;18;354:2200.
4. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16:1167-1171.
5. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 2006;40:476-481.
6. Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticosteroid resistant ulcerative colitis. A randomized controlled trial. Gut. 2003;52:998-1002.
7. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomosis complications and function in 1005 patients. Ann Surg. 1995;222:120-127.
8. Rugeerts P, d'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factory antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
9. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agents. N Engl J Med. 2001;345:1098-1104.
10. Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
11. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853.
12. Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4:1135-1142.
13. Lichtenstein GR, Feagan B, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
14. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-883.
15. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study. Aliment Pharmacol Ther. 2004;19:749-754.
16. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747-1753.
17. Dhillon S, Loftus EV Jr, Tremaine WJ, et al. The natural history of surgery for ulcerative colitis in a population-based cohort from Olmsted County, Minnesota. Am J Gastroenterol. 2005;100:A819.
18. Faubion WA Jr, Loftus EV, Hamsen WS, et al. The natural history of corticosteroid for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
19. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis. A meta-analysis. Gut. 2001;48:526-535.
20. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123-128.